ArticleArchives of medical science : AMS2024
A study on the global burden of non-melanoma skin cancer from 1990 to 2019.
Article in Archives of medical science : AMS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Photoprotective and genoprotective effects of theophylline against UVB-induced damage in normal human dermal fibroblasts.Molecular biology reports · 2026Article
- Global co-occurrence patterns of cancer and cardiovascular disease: a comprehensive analysis based on the Global Burden of Disease Study 2021.Archives of medical science : AMS · 2026Article
- Global, regional, and national incidence, mortality, DALY, and prevalence rates of orofacial clefts in children and adolescents from 1990 to 2021, with predictions to 2050.Archives of medical science : AMS · 2026Article
- Incidence and mortality of nonmelanoma skin cancer in Europe: current trends and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Ten Years of Euromelanoma in Hungary: Nationwide Trends and Risk Factors for Skin Cancer in Central-Eastern Europe.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to provide an overview and analysis of the global disease burden of non-melanoma skin cancer using data from the Global Burden of Disease 2019 (GBD 2019) database. Material and methods: This study utilized the global GBD 2019 disease data. The data were categorized into various subgroups based on region, sociodemographic index (SDI), country, gender, and age. We analyzed incident cases, incidence rate, disability-adjusted life years (DALYs), DALY rate, as well as age-standardized indicators and their annualized percent change (EAPC). Results: The global burden of non-melanoma skin cancer exhibited an increasing trend from 1990 to 2019. The EAPC for the age standardized incidence rate (ASIR) was 1.13, and the EAPC for the age standardized DALY rate was 0.20. Geographic variations were observed, with the most substantial increase in ASIR observed in high-income North America (EAPC = 2.20), and a significant increase in the age standardized DALY rate in Central Asia (EAPC = 2.32). Countries with a high SDI had the highest ASIR and showed the most significant increasing trend (EAPC = 1.97). Overall, the burden of disease for nonmelanoma skin cancer increased in all countries globally from 1990 to 2019. The EAPC for incident cases, DALYs, and ASIR was greater than 0 in almost all countries worldwide, indicating an overall increasing trend. Conclusions: The global disease burden of non-melanoma skin cancer ex-hibited significant increasing changes from 1990 to 2019. Several countries in Asia, Africa, and North America experienced a severe disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.